Markets:

Overview

News

Currencies

International

Treasuries

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (NY:HLN)

11.13 -0.09 (-0.76%)

Streaming Delayed Price Updated: 9:48 AM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 Next >

Kimberly-Clark's Mega-Bid for Kenvue: A $48.7 Billion Consumer Staples Shakeup

January 28, 2026

In a move that signals a seismic shift within the consumer staples landscape, Kimberly-Clark (NYSE:KMB) is on the precipice of finalizing its $48.7 billion acquisition of Kenvue (NYSE:KVUE). This...

Via MarketMinute

Topics Economy

The New Titan of Wellness: Kimberly-Clark’s $48.7 Billion Kenvue Acquisition Reshapes Consumer Staples

January 20, 2026

In a bold move to transcend its identity as a legacy paper commodities giant, Kimberly-Clark (NYSE: KMB) has launched a massive $48.7 billion bid to acquire Kenvue (NYSE: KVUE), the consumer health...

Via MarketMinute

Topics Initial Public Offering Supply Chain

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Top 2 Risk Off Stocks That May Implode In August ↗

August 09, 2024

Via Benzinga

Current Analysis: Haleon ↗

March 12, 2024

Haleon (HLN) is one of the largest consumer health companies in the world. Over the past year, Haleon PLC share price rose 13.8% from $7.60 to $8.66 as of Tuesday’s market close.

Via Talk Markets

Kenvue Insider Buying and the Kimberly-Clark Megamerger: A Value Investor's Deep Dive

December 25, 2025

As 2025 draws to a close, the consumer staples sector is witnessing one of its most dramatic transformations in decades. The recent announcement that Kimberly-Clark (NYSE:KMB) will acquire Kenvue...

Via MarketMinute

Topics Lawsuit

Kenvue's Megadeal Fuels Stock Market Rise at Week's Start: A New Consumer Health Giant Emerges

November 03, 2025

The financial markets have kicked off the week with a significant surge, largely propelled by the blockbuster acquisition of Kenvue Inc. (NYSE: KVUE) by Kimberly-Clark Corporation (NYSE: KMB). This...

Via MarketMinute

Topics Supply Chain

Salesforce Strengthens AI Offerings Via Vonage, Haleon Tie-Ups ↗

October 08, 2025

Salesforce (NYSE: CRM) partners with Vonage and Haleon to expand AI, Cloud, and 5G innovation using Data Cloud and Agentforce solutions.

Via Benzinga

Topics Artificial Intelligence

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026 ↗

September 29, 2025

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma...

Via Benzinga

NEXGEL Inc. Equity Warrants: A High-Stakes Bet on Future Profitability Amidst Rapid Growth

September 27, 2025

Langhorne, PA – September 27, 2025 – Investors in NEXGEL Inc. (NASDAQ: NXGL), a company at the forefront of hydrogel technology, are closely watching the trajectory of its equity warrants (NXGLW)....

Via MarketMinute

Topics Intellectual Property

Kenvue Bounces Off Record Low: A Deep Dive into its Rebound and Future Prospects

September 24, 2025

Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has experienced a significant rebound in its stock price, climbing notably from a recent record low. This resurgence...

Via MarketMinute

Topics Government Product Recall

This Warner Bros. Discovery Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

September 16, 2025

Via Benzinga

Under the Radar: Hidden Value Across the Atlantic – 3 Stocks to Watch ↗

July 22, 2025

Via Benzinga

KKR Outbids Competitors To Secure $2.9 Billion Karo Healthcare Takeover ↗

April 09, 2025

KKR is closing in on a $2.9B takeover of Karo Healthcare after outbidding rivals, reinforcing its aggressive push into European healthcare.

Via Benzinga

Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion ↗

March 19, 2025

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's largest shareholder with over 5%.

Via Benzinga

Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025 ↗

February 27, 2025

Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half.

Via Benzinga

Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business ↗

January 23, 2025

Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

Via Benzinga

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy ↗

December 18, 2024

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.

Via Investor's Business Daily

What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday? ↗

December 16, 2024

Pfizer's 2025 guidance to be revealed Tuesday. Goldman Sachs predicts $64.9 billion revenue and EPS of $3.13, supported by Paxlovid and Eliquis growth.

Via Benzinga

What's Going On With Kenvue Stock Monday? ↗

October 21, 2024

Kenvue Inc. (NYSE:KVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company.

Via Benzinga

Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies ↗

October 21, 2024

Elf Beauty appeared to rally along with KVUE on Monday.

Via Investor's Business Daily

Topics Stocks

World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice ↗

October 11, 2024

Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on...

Via Benzinga

Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon ↗

October 01, 2024

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.

Via Benzinga

Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff ↗

September 25, 2024

Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks...

Via Benzinga

Upcoming Stock Spinoffs: Should You Pounce or Pass? ↗

July 04, 2024

Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.

Via InvestorPlace

Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M ↗

June 26, 2024

Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth...

Via Benzinga

Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC ↗

June 26, 2024

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

Via Benzinga

GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale ↗

May 17, 2024

GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers.

Via Benzinga

Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B ↗

March 18, 2024

Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon.

Via Benzinga

Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars ↗

February 29, 2024

Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit rises 10.4% to £2.55 billion. CEO Brian McNamara outlines solid financial...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.